Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727158 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL16117460 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL1295960 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL15590800 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL2953605 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL16117467 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL30850208 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL3944070 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL12653679 | 0.98 | SLC6A2 (0.49) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL13081194 | 0.98 | SLC6A2 (0.49) | SLC6A2SLC6A4CYP2C19ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113292433-A | Synthesis method of trans-1, 2-cyclohexane dicarboxylic acid monomethyl ester | 上海凌凯医药科技有限公司 | 2021-08-24 | — | — | CN | claimed |
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-02-27 | — | — | US | disclosed |
| EP-4452965-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-10-30 | — | — | EP | disclosed |
| CN-117659022-A | Ureido substituted pyridine compound, pharmaceutical composition containing ureido substituted pyridine compound and medical application of ureido substituted pyridine compound | 苏州阿尔脉生物科技有限公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023118253-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-06-29 | — | — | WO | disclosed |
| CN-115989220-A | Amido cyclohexanoic acid derivatives as LPA receptor inhibitors | 奇斯药制品公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-3054947-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3104705-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3104705-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-03 | — | — | EP | disclosed |
| CN-113292433-A | Synthesis method of trans-1, 2-cyclohexane dicarboxylic acid monomethyl ester | 上海凌凯医药科技有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1392676-B1 | HETEROCYCLIC UREA DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1688412-A2 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-19 | — | — | US | disclosed |
| US-6103761-A | Agents acting at cholecystokinin receptors | WARNER-LAMBERT COMPANY (US) | 2000-08-15 | — | — | US | disclosed |
| US-5389682-A | Appetite suppressants, anxiolytic agents, gastric acid inhibition | WARNER-LAMBERT COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
| WO-1994006757-A1 | AGENTS ACTING AT CHOLECYSTOKININ RECEPTORS | WARNER-LAMBERT COMPANY (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | SLC6A2 338/4885SLC6A4 449/4885CYP2C19 800/4885 |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | SLC6A2 338/4885SLC6A4 449/4885CYP2C19 800/4885 |
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | SLC6A2 3792/4885SLC6A4 4646/4885CYP2C19 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.